The “Creating and Restoring Equal Access To Equivalent Samples Act of 2017” or the “CREATES Act of 2017” is a bill in the Senate that is intended to expedite the development of generic... read more
The “Creating and Restoring Equal Access To Equivalent Samples Act of 2017” or the “CREATES Act of 2017” is a bill in the Senate that is intended to expedite the development of generic... read more
UCB announced on 4/27/18 that the European Committee for Medicinal Products for Human Use (CHMP) has recommended approval of a label extension for Cimzia (certolizumab pegol), to include a new... read more
Eloxx Pharmaceuticals, Inc. (“Eloxx”), (NASDAQ:ELOX), announced on 4/27/18 that it has received orphan-drug designation from the Food and Drug Administration (FDA) for ELX-02 for treatment of... read more
Gilead Sciences, Inc. (NASDAQ:GILD) today announced on 4/27/18 the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), has... read more
Proniras Corporation, an Accelerator Life Science Partners portfolio company, announced on 4/27/18 that it has been awarded a contract potentially worth $89.5 million from the U.S. Department of... read more